Antifungal Activity of 3-Hydrazinoquinoxaline-2-Thiol, a Novel Quinoxaline Derivative Against Candida Species

Overview

Journal Mycobiology

Date 2024 Jul 1

PMID 38948451

Authors

Abdelbagi Elfadil

Karem Ibrahem

Affiliations

Soon will be listed here.

Abstract

ranks as among the most frequently encountered fungal infections that associated with high morbidity and mortality. Quinoxaline derivatives are a group of small molecules that showed a promising antimicrobial activity. This study aimed to investigate the fungicidal effects of 3-hydrazinoquinoxaline-2-thiol against in comparison with Amphotericin B as a reference. Also, we aim to assess the efficacy of 3-hydrazinoquinoxaline-2-thiol using mice oral candidiasis model. Fifty-six isolates were subjected to susceptibility testing by broth microdilution method for 3-hydrazinoquinoxaline-2-thiol and Amphotericin B. Therefore, Minimal inhibitory concentrations (MIC) were assessed and compared. The oral candidiasis mice model was used to evaluate the activity of 3-hydrazinoquinoxaline-2-thiol . Microbiological evaluation of progression and ELISA were used in this study. 3-hydrazinoquinoxaline-2-thiol was more effective than Amphotericin B against most clinical isolates of . Higher effectiveness was seen against and isolates. However, the efficiency against isolates varies. 3-hydrazinoquinoxaline-2-thiol was also effective against and . 3-hydrazinoquinoxaline-2-thiol showed a good efficacy in mice model against cells ATCC 10231. 3-hydrazinoquinoxaline-2-thiol has shown promising antifungal and anti-inflammatory activity against different species. More tests and experiments are needed.

References

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Patil S, Rao R, Majumdar B, Anil S . Clinical Appearance of Oral Candida Infection and Therapeutic Strategies. Front Microbiol. 2016; 6:1391. PMC: 4681845. DOI: 10.3389/fmicb.2015.01391. View

Jose P, Alvarez-Lerma F, Maseda E, Olaechea P, Peman J, Soriano C . Invasive fungal infection in crtically ill patients: hurdles and next challenges. J Chemother. 2019; 31(2):64-73. DOI: 10.1080/1120009X.2018.1557799. View

Groll A, Townsend R, Desai A, Azie N, Jones M, Engelhardt M . Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017; 19(5). DOI: 10.1111/tid.12751. View

Barchiesi F, Orsetti E, Osimani P, Catassi C, Santelli F, Manso E . Factors related to outcome of bloodstream infections due to Candida parapsilosis complex. BMC Infect Dis. 2016; 16:387. PMC: 4977692. DOI: 10.1186/s12879-016-1704-y. View

Mikkelsen K, Sirisarn W, Alharbi O, Alharbi M, Liu H, Nohr-Meldgaard K . The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids. Int J Antimicrob Agents. 2021; 57(3):106283. DOI: 10.1016/j.ijantimicag.2021.106283. View

Hutchings M, Truman A, Wilkinson B . Antibiotics: past, present and future. Curr Opin Microbiol. 2019; 51:72-80. DOI: 10.1016/j.mib.2019.10.008. View

Pappas P, Kauffman C, Andes D, Clancy C, Marr K, Ostrosky-Zeichner L . Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2015; 62(4):e1-50. PMC: 4725385. DOI: 10.1093/cid/civ933. View

von Lilienfeld-Toal M, Wagener J, Einsele H, Cornely O, Kurzai O . Invasive Fungal Infection. Dtsch Arztebl Int. 2019; 116(16):271-278. PMC: 6549129. DOI: 10.3238/arztebl.2019.0271. View

10.

Jacobs S, Zagaliotis P, Walsh T . Novel antifungal agents in clinical trials. F1000Res. 2022; 10:507. PMC: 8787557. DOI: 10.12688/f1000research.28327.2. View

11.

de Oliveira Santos G, Vasconcelos C, Lopes A, de Sousa Cartagenes M, Filho A, do Nascimento F . Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents. Front Microbiol. 2018; 9:1351. PMC: 6038711. DOI: 10.3389/fmicb.2018.01351. View

12.

Mota Fernandes C, Dasilva D, Haranahalli K, McCarthy J, Mallamo J, Ojima I . The Future of Antifungal Drug Therapy: Novel Compounds and Targets. Antimicrob Agents Chemother. 2020; 65(2). PMC: 7848987. DOI: 10.1128/AAC.01719-20. View

13.

Cheng G, Sa W, Cao C, Guo L, Hao H, Liu Z . Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions. Front Pharmacol. 2016; 7:64. PMC: 4800186. DOI: 10.3389/fphar.2016.00064. View

14.

Mayer F, Kronstad J . Discovery of a Novel Antifungal Agent in the Pathogen Box. mSphere. 2017; 2(2). PMC: 5390095. DOI: 10.1128/mSphere.00120-17. View

15.

Miceli M, Kauffman C . Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis. 2015; 61(10):1558-65. DOI: 10.1093/cid/civ571. View

16.

Parente-Rocha J, Bailao A, Amaral A, Taborda C, Paccez J, Borges C . Antifungal Resistance, Metabolic Routes as Drug Targets, and New Antifungal Agents: An Overview about Endemic Dimorphic Fungi. Mediators Inflamm. 2017; 2017:9870679. PMC: 5485324. DOI: 10.1155/2017/9870679. View

17.

Tan C, Therien A, Lu J, Lee S, Caron A, Gill C . Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Sci Transl Med. 2012; 4(126):126ra35. DOI: 10.1126/scitranslmed.3003592. View

18.

Ashley E . Antifungal Drugs: Special Problems Treating Central Nervous System Infections. J Fungi (Basel). 2019; 5(4). PMC: 6958367. DOI: 10.3390/jof5040097. View

19.

Gonzales P, Pesesky M, Bouley R, Ballard A, Biddy B, Suckow M . Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA. Nat Chem Biol. 2015; 11(11):855-61. PMC: 4618095. DOI: 10.1038/nchembio.1911. View

20.

Takakura N, Sato Y, Ishibashi H, Oshima H, Uchida K, Yamaguchi H . A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush. Microbiol Immunol. 2003; 47(5):321-6. DOI: 10.1111/j.1348-0421.2003.tb03403.x. View